ALK阳性-话题@MedSci

#ALK阳性#

68篇内容 | 2290人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1987510, encodeId=0739198e51026, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, objectType=article, longId=43675, objectId=ea41436e517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea41436e517, replyNumber=0, likeNumber=96, createdTime=2015-04-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea41436e517, moduleTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea41436e517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987509, encodeId=6625198e50905, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, objectType=article, longId=37519, objectId=234f3e51952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234f3e51952, replyNumber=0, likeNumber=77, createdTime=2014-09-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234f3e51952, moduleTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234f3e51952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987508, encodeId=f0f6198e508dd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ASCO 2014：陆舜谈ALK阳性肺癌的PROFILE 1014研究, objectType=article, longId=35698, objectId=5a283569845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a283569845, replyNumber=0, likeNumber=66, createdTime=2014-12-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a283569845, moduleTitle=ASCO 2014：陆舜谈ALK阳性肺癌的PROFILE 1014研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a283569845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987506, encodeId=0df5198e50612, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ASCO 2014：克唑替尼一线治疗晚期ALK阳性非鳞NSCLCIII期临床结果, objectType=article, longId=35008, objectId=5921350089f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5921350089f, replyNumber=0, likeNumber=73, createdTime=2014-05-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5921350089f, moduleTitle=ASCO 2014：克唑替尼一线治疗晚期ALK阳性非鳞NSCLCIII期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5921350089f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987507, encodeId=e9e0198e50770, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观, objectType=article, longId=35662, objectId=312b35662d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=312b35662d6, replyNumber=0, likeNumber=68, createdTime=2014-10-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=312b35662d6, moduleTitle=ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=312b35662d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987505, encodeId=365b198e50502, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JNCI：克里唑蒂尼治疗晚期化疗抵抗性ALK阳性淋巴瘤安全有效, objectType=article, longId=31067, objectId=fcd23106e99, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcd23106e99, replyNumber=0, likeNumber=102, createdTime=2014-09-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcd23106e99, moduleTitle=JNCI：克里唑蒂尼治疗晚期化疗抵抗性ALK阳性淋巴瘤安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcd23106e99)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987503, encodeId=9e6e198e5032d, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, objectType=article, longId=25138, objectId=454325138e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=454325138e0, replyNumber=0, likeNumber=69, createdTime=2014-01-06, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454325138e0, moduleTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454325138e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987502, encodeId=5270198e50296, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗, objectType=article, longId=19948, objectId=7ed71994855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ed71994855, replyNumber=0, likeNumber=69, createdTime=2013-07-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ed71994855, moduleTitle=NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ed71994855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987504, encodeId=130b198e5041f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=WCLC 2013：新型抑制剂治疗克唑替尼失败后 ALK阳性晚期NSCLC, objectType=article, longId=26416, objectId=3e6c264166c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e6c264166c, replyNumber=0, likeNumber=107, createdTime=2014-04-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e6c264166c, moduleTitle=WCLC 2013：新型抑制剂治疗克唑替尼失败后 ALK阳性晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e6c264166c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK阳性

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期

2015-04-22

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理

2014-09-24

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ASCO 2014：陆舜谈ALK阳性肺癌的PROFILE 1014研究

2014-12-09

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ASCO 2014：克唑替尼一线治疗晚期ALK阳性非鳞NSCLCIII期临床结果

2014-05-24

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观

2014-10-01

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JNCI：克里唑蒂尼治疗晚期化疗抵抗性ALK阳性淋巴瘤安全有效

2014-09-02

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌

2014-01-06

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗

2013-07-11

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

WCLC 2013：新型抑制剂治疗克唑替尼失败后 ALK阳性晚期NSCLC

2014-04-24

科室
- - 订阅+
  - 更多科室
工具
服务